Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myelodysplastic Syndromes
Description
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. MeSH
Hierarchy View
Subtype Terms (4)
Anemia, Refractory
61 drugs (35 approved, 26 experimental)
GATA2 Deficiency
10 drugs (8 approved, 2 experimental)
Hemoglobinuria, Paroxysmal
45 drugs (22 approved, 23 experimental)
Approved Indicated Drugs (6)
Phase 3 Indicated Drugs (83)
Phase 2 Indicated Drugs (186)
allogeneic natural killer cells
autologous expanded mesenchymal stem cells oti-010
autologous mesenchymal stem cells
cord blood hematopoietic stem cell
cytokine induced memory-like nk cells
freeze-dried black raspberry powder
gamma-glutamyl-s-(benzyl)-cysteinyl-r(-)-phenylglycine diethyl ester
gvax pancreatic cancer vaccine
haplo-identical hematopoietic stem cells
human fecal microbiota (Reybota)
interferon alpha-2b (Intron-A)
lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)
Phase 1 Indicated Drugs (191)
aldhbr umbilical cord blood cells
anti-ley-scfv-cd28-zeta vector
brentuximab vedotin (adcetris)
cd25-depleted peripheral blood mononuclear cell
cd34-tk75 transduced donor lymphocytes
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
chimeric antigen receptor t cells, eps8 or wt1 peptide specific dendritic cell
dec-205/ny-eso-1 fusion protein cdx-1401
donor memory t cells that have been depleted of cd62l+
in111 anti-cd45 monoclonal antibody bc8
interferon gamma (ifnγ)-primed human bone marrow-derived mesenchymal stromal cells
Other Experimental Indicated Drugs (20)
Organization Involved with Phase 4 Indications (23)
Organization Involved with Phase 3 Indications (138)
Albert Einstein Israelite Hospital
ASO SS Antonio e Biagio e C Arrigo Alessandria, Italy
Assistance Publique - Hôpitaux de Paris
Badalona Hospital Germans Trias i Pujol
Blood and Marrow Transplant Clinical Trials Network
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
Center for International Blood and Marrow Transplant Research
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Cohen Children's Medical Center of New York
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)
Eastern Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer
European Working Group of MDS in Childhood
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Fondazione Italiana Diabete Onlus
Groupe Francophone des Myelodysplasies
Gruppo Italiano Malattie EMatologiche dell'Adulto
HOVON - Dutch Haemato-Oncology Association
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Oregon Health and Science University
Royal Marsden Hospital NHS Trust
Shanghai 6th People's Hospital
Shanghai institute of Hematology
Shanghai Ruijin Hospital North
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Technical University of Dresden
The Canadian Blood and Marrow Transplant Group
The Christie NHS Foundation Trust
Organization Involved with Phase 2 Indications (288)
Asociación Andaluza de Hematología y Hemoterapia
Azienda Ospedaliera Antonio Cardarelli
Bambino Gesù Hospital and Research Institute
BioMed Valley Discoveries, Inc
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Cell Therapy Transplant Canada
Chao Family Comprehensive Cancer Center
Children's Hospital Los Angeles
City of Hope National Medical Center
Ciusss de L'Est de l'Île de Montréal
Colorado Blood Cancer Institute
Cyclacel Pharmaceuticals, Inc.
Department of Health and Human Services
Department of Health, United Kingdom
Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Good Samaritan Hospital, Cincinnati
Herbert Irving Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
Hoosier Cancer Research Network
Inner Mongolia International Mongolian Hospital
Korea Research Institute of Bioscience & Biotechnology
Lixte Biotechnology Holdings, Inc.
Louis A. Weiss Memorial Hospital
Medical University of South Carolina
Memorial Sloan-Kettering Cancer Center
Moorgreen Hospital, Southampton
National Cancer Institute, France
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
New York Presbyterian Hospital
North Central Cancer Treatment Group
Our Lady of Mercy Medical Center
Pavlov First Saint Petersburg State Medical University
Pediatric Brain Tumor Consortium
QOL-ONE Associazione Culturale e di Ricerca
Sclnow Biotechnology Co., Ltd.
service Hématologie Séniors Hôpital Saint Louis
The Korean Society of Blood and Marrow Transplantation
The University of Texas, Dallas
The Wayne D. Kuni and Joan E. Kuni Foundation
Tokyo Metropolitan Komagome Hospital
Universita' Cattolica del Sacro Cuore
Université catholique de Louvain
University Hospital of Mont-Godinne
University of Alabama, Birmingham
University of California, Davis
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Illinois at Chicago
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Southern California
University of Southern Denmark
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (95)
Alex's Lemonade Stand Foundation
American Society for Blood and Marrow Transplantation
Chinese Academy of Medical Sciences
CLL Global Research Foundation
Damon Runyon Cancer Research Foundation
Innovent Biologics (Suzhou) Co. Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National University of Singapore
Pacific Cancer Medical Center Inc.
Organization Involved with Other Experimental Indications (14)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
